Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence


Aims and background

The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence.

Patients and methods

Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence.


Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgRpos), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgRneg), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgRloss). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgRneg compared with PgRpos, and 2.93 (95% CI: 1.51-5.70) for PgRloss compared with PgRpos.


PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.

Tumori 2015; 101(4): 398 - 403




Giuseppe Bogina, Gianluigi Lunardi, Francesca Coati, Giuseppe Zamboni, Stefania Gori, Laura Bortesi, Marcella Marconi, Paola Agnese Cassandrini, Monica Turazza, Laura Cortesi, Elisabetta DeMatteis, Guido Ficarra, Toni Ibrahim, Patrizia Serra, Laura Medri, Sara Giraudi, Matteo Lambertini, Franca Carli, Jennifer Foglietta, Angelo Sidoni, Martina Nunzi, Corrado Ficorella, Maria Rosaria Diadema, Lucia Del Mastro

Article History


Financial support: None.
Conflict of interest: All authors declare they have no conflict of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  • Sacro Cuore-Don Calabria Hospital of Negrar, Verona - Italy
  • University of Modena and Reggio Emilia, Modena - Italy
  • Istituto Scientifico Romagnolo per la Cura dei Tumori of Meldola, Forlì - Italy
  • Morgagni-Pierantoni Hospital, Forlì - Italy
  • IRCCS AOU San Martino-IST, Genoa - Italy
  • Azienda Ospedaliera of Perugia, Perugia - Italy
  • University of Perugia, Perugia - Italy
  • AO Santa Maria, Terni - Italy
  • San Salvatore Hospital, University of L’Aquila, L’Aquila - Italy
  • II University of Naples, Naples - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.